VEGFA and neoplasm: Multiple Food and Drug Administration (FDA) approved therapeutic interventions exist for the treatment of CRC, many of which aim to inhibit tumor angiogenesis by targeting the VEGF pathway, e.g. Nintedanib (Boehringer Ingelheim), Cyramza (Eli Lilly), Sunitinib (Pfizer), Regorafenib (Bayer), and Bevacizumab (Roche) the overall impact of these therapies remains extremely poor.